Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market ...

Peptide companies' are creating knock-off versions of these drugs that have not been approved by the FDA and contain ...

Men, Baby Boomers, and postgraduate degree-holders were among those most likely to say they wouldn’t choose medication over ...

These drugs work similarly but differ in dosage and specific indications (uses). Research suggests that tirzepatide is more ...

Novo Nordisk , whose global profile has risen along with demand for its Wegovy weight-loss drug, is bolstering operations in ...

Data readouts over the next six months could set expectations for how the highly lucrative market for weight loss therapies ...

Eli Lilly anticipates regulatory approval for its weight-loss drug Zepbound in Japan by mid-2025, boosting its global ...

Allowing Medicare to cover popular weight loss drugs such as Wegovy and Zepbound could increase federal spending by billions ...

The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

New weight loss drugs like Wegovy and Zepbound have been heralded as game-changers in tackling obesity, helping people lose significant amounts of weight and potentially prevent Type 2 diabetes.

However, as of September 2024, the FDA has marked all Zepbound doses as available. One alternative may be Wegovy, another FDA-approved drug for weight management. Read our recommendations on how ...